$8.38
1.58% yesterday
Nasdaq, Oct 17, 09:48 pm CET
ISIN
US29772L1089
Symbol
ETON
Sector
Industry

Eton Pharmaceuticals, Inc. Stock price

$8.40
+2.68 46.85% 1M
+5.26 167.52% 6M
+4.02 91.78% YTD
+4.25 102.41% 1Y
+3.25 63.11% 3Y
+2.27 37.03% 5Y
+2.15 34.40% 10Y
Nasdaq, Closing price Thu, Oct 17 2024
+0.15 1.82%
ISIN
US29772L1089
Symbol
ETON
Sector
Industry

Key metrics

Market capitalization $217.02m
Enterprise Value $204.21m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 6,807.00
EV/Sales (TTM) EV/Sales 6.51
P/S ratio (TTM) P/S ratio 6.92
P/B ratio (TTM) P/B ratio 16.06
Revenue growth (TTM) Revenue growth 8.14%
Revenue (TTM) Revenue $31.38m
EBIT (operating result TTM) EBIT $-6.28m
Free Cash Flow (TTM) Free Cash Flow $30.00k
Cash position $17.69m
EPS (TTM) EPS $-0.26
P/E forward negative
P/S forward 5.85
EV/Sales forward 5.50
Short interest 0.51%
Show more

Is Eton Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Eton Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Eton Pharmaceuticals, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Eton Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from Eton Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
31 31
8% 8%
100%
- Direct Costs 13 13
67% 67%
41%
19 19
13% 13%
59%
- Selling and Administrative Expenses 19 19
5% 5%
59%
- Research and Development Expense 5.28 5.28
58% 58%
17%
-5.27 -5.27
1,564% 1,564%
-17%
- Depreciation and Amortization 1.01 1.01
19% 19%
3%
EBIT (Operating Income) EBIT -6.28 -6.28
1,196% 1,196%
-20%
Net Profit -6.69 -6.69
2,809% 2,809%
-21%

In millions USD.

Don't miss a Thing! We will send you all news about Eton Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eton Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
15 days ago
Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions
Neutral
GlobeNewsWire
about 2 months ago
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.
Neutral
Seeking Alpha
2 months ago
Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eaton Pharmaceuticals Second Quarter 2024 Financ...
More Eton Pharmaceuticals, Inc. News

Company Profile

Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. It focuses on product candidates that are liquid in formulation, including injectables, oral liquids and ophthalmics. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Head office United States
CEO Sean Brynjelsen
Employees 30
Founded 2017
Website www.etonpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today